Morepen Laboratories Limited

Drug Manufacturers-Specialty & Generic

Prices are adjusted according to historical splits.

Morepen Laboratories Limited Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
₹20.39 billion
Book Value:
Revenue TTM:
₹15.24 billion
Operating Margin TTM:
Gross Profit TTM:
₹4.44 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Morepen Laboratories Limited had its IPO on under the ticker symbol MOREPENLAB.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Morepen Laboratories Limited has a staff strength of 0 employees.

Stock update

Shares of Morepen Laboratories Limited opened at ₹39.14 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹35.71 - ₹39.14, and closed at ₹35.98.

This is a -7.36% slip from the previous day's closing price.

A total volume of 497,421 shares were traded at the close of the day’s session.

In the last one week, shares of Morepen Laboratories Limited have slipped by -7.93%.

Morepen Laboratories Limited's Key Ratios

Morepen Laboratories Limited has a market cap of ₹20.39 billion, indicating a price to book ratio of 2.1194 and a price to sales ratio of 1.064.

In the last 12-months Morepen Laboratories Limited’s revenue was ₹15.24 billion with a gross profit of ₹4.44 billion and an EBITDA of ₹1.01 billion. The EBITDA ratio measures Morepen Laboratories Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Morepen Laboratories Limited’s operating margin was 4.58% while its return on assets stood at 3.31% with a return of equity of 5.81%.

In Q2, Morepen Laboratories Limited’s quarterly earnings growth was a positive 163.6% while revenue growth was a positive 33%.

Morepen Laboratories Limited’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at ₹0.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Morepen Laboratories Limited’s profitability.

Morepen Laboratories Limited stock is trading at a EV to sales ratio of 1.0497 and a EV to EBITDA ratio of 13.2404. Its price to sales ratio in the trailing 12-months stood at 1.064.

Morepen Laboratories Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
₹11.10 billion
Total Liabilities
₹3.21 billion
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Morepen Laboratories Limited ended 2024 with ₹11.10 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹11.10 billion while shareholder equity stood at ₹7.53 billion.

Morepen Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.21 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹744.74 million in goodwill. Its cash balance stood at ₹216.66 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹9.34 million.

Morepen Laboratories Limited’s total current assets stands at ₹7.56 billion while long-term investments were ₹0 and short-term investments were ₹401.52 million. Its net receivables were ₹2.63 billion compared to accounts payable of ₹2.27 billion and inventory worth ₹2.29 billion.

In 2024, Morepen Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Morepen Laboratories Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Morepen Laboratories Limited stock is currently trading at ₹35.98 per share. It touched a 52-week high of ₹48.4 and a 52-week low of ₹48.4. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹34 and 200-day moving average was ₹30.1 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4829.2% of the company’s stock are held by insiders while 85.6% are held by institutions.

Frequently Asked Questions About Morepen Laboratories Limited

The stock symbol (also called stock or share ticker) of Morepen Laboratories Limited is MOREPENLAB

The IPO of Morepen Laboratories Limited took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Morepen Laboratories Limited operates as a pharmaceutical and healthcare products company in India. The company manufactures active pharmaceutical ingredients (APIs), home diagnostics, formulations, and over the counter products. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic drugs, anti- coagulant, anti-gout, and anti- malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, blood glucose test strips, and heat belt. It also provides Burnol, first degree/minor burns cream; Fiber-X, a sat isabgol; fever X for fever; Pain X for pain; Acidity X for acidity; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti- allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers its over-the-counter products under the Dr. Morepen brand. It also exports its products. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.